Reimbursement Listing of Ipragliflozin Expected in April; 4 Rival SGLT-2 Inhibitors Seen to Follow Suit 1 Month Later

Leading the pack of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, Astellas Pharma’s antidiabetic agent ipragliflozin L-proline won the backing of a key health ministry panel last week, which set the stage for its marketing approval in January next year. Yet the battle...read more